Why AI May Increase Cognitive Burden Before Reducing It

Jun 18, 2026 | Biotech

Image Source: ChatGpt Generated
Written by: Deepak Shukla
On behalf of: Wellness in Italy

It seems that artificial intelligence is being proposed as an answer to what could be considered as one of the most serious problems facing the life sciences sector – the problem of information overload.

There has never been as much data, documentation, literature, and administration for healthcare providers, researchers, regulators, and pharmaceutical companies to deal with.

With all of the above, AI offers some obvious advantages in terms of automation, faster analyses, pattern recognition, and decision making.

All of the above can definitely come true in due course of time.

However, there is another side of things developing in the clinical, research, and regulatory spheres.

Prior to relieving professionals of their cognitive burdens, AI will only add to them.

They must evaluate them.

AI Is Not Eliminating Decisions. It Is Changing Their Nature

Much of the public discussion around AI assumes that automation reduces the number of decisions professionals need to make.

In life sciences, the reality is often more complex.

The scientist may spend less time on manual literature review, but greater time ensuring the generated summary of literature represents the source material correctly.

The doctor may spend less time writing down documentation of interactions but greater time verifying that the AI-generated documentation is comprehensive and correct.

The regulatory affairs specialist may leverage AI technology to prepare documents quickly yet bear responsibility for accuracy of each document submitted.

The task changes.

The accountability does not.

As a result, professionals often find themselves making a different category of decision: deciding whether the AI itself can be trusted.

That assessment requires attention, expertise, and mental energy.

The Cognitive Cost of Verification

One of the most overlooked consequences of AI adoption is the mental effort associated with validation.

In clinical and research settings, verification is not optional.

The physician who examines documents assisted by AI is responsible for the health of patients.

The researcher who conducts research assisted by AI is responsible for the correctness of results.

The pharmacovigilance expert who examines signals detected with the help of AI needs to assess whether the signals are genuine or fake.

The process frequently follows the same pattern:

The AI generates an output.

The professional reviews it.

The professional evaluates its accuracy.

The professional decides whether further review is required.

The professional accepts, rejects, or modifies the recommendation.

Each individual step may appear minor.

Repeated hundreds of times across a working week, however, they create a form of cognitive friction that many organisations are only beginning to recognise.

More Information Can Create More Mental Work

AI systems often generate multiple interpretations, recommendations, summaries, risk assessments, or possible courses of action.

This can be extremely valuable.

It can also create new demands on attention.

For example, a clinical researcher might receive several potential interpretations of a dataset.

A medical affairs team may receive multiple AI-generated content variations.

A regulatory professional may receive several suggested approaches to document preparation.

While these options expand capability, they also create additional evaluation requirements.

Which recommendation is most accurate?

Which carries the lowest risk?

Which aligns most closely with regulatory expectations?

Which interpretation deserves further investigation?

In environments where accuracy matters, additional options frequently require additional scrutiny.

Healthcare Professionals Face a Unique Challenge

Healthcare is potentially the most striking illustration of this phenomenon.

Clinical decision-making inherently has aspects of uncertainty, lack of information, and substantial responsibility.

AI can have tremendous promise in decreasing administrative burden and aiding clinical decision-making.

Yet healthcare professionals must simultaneously determine where AI adds value and where human judgment remains essential.

This creates an important transition period.

It is not merely about clinical decision-making.

It can often entail knowing when you should trust an AI-based decision and when you need to dig deeper.

Such vigilance of cognition may require mental effort even when the technology is working efficiently.

Regulatory and Compliance Teams May Experience Similar Pressures

The life sciences industry is one of the most heavily-regulated industries that cannot compromise on accuracy and quality of documentation.

AI can streamline a lot of documentation tasks.

However, faster content generation does not remove regulatory accountability.

In some cases, AI may even increase the need for oversight during early adoption phases.

Teams must understand how outputs were generated.

They must identify potential inaccuracies.

They must establish governance frameworks.

They must document review processes.

The result is that efficiency gains can initially coexist with increased cognitive workload.

Decision Fatigue Is Not Simply About Volume

Decision fatigue is often associated with making large numbers of choices.

In reality, ambiguity frequently contributes just as much mental strain.

AI introduces new forms of ambiguity because professionals must assess both the recommendation itself and the reliability of the system generating it.

This creates what might be described as a second layer of decision-making.

People are no longer only evaluating the evidence.

They are evaluating the tool interpreting the evidence.

In clinical, research, and regulatory environments, that distinction matters enormously.

Why This Challenge Is Likely Temporary

Despite these concerns, there are strong reasons for optimism.

Historically, new technologies often create temporary complexity before creating simplicity.

Organisations develop governance structures.

Professionals gain familiarity.

Validation processes become more efficient.

Trust frameworks mature.

Over time, many of the cognitive demands associated with evaluating AI outputs may become more manageable.

The current challenge is therefore less about technological capability and more about organisational adaptation.

The Real Opportunity

The life sciences industry should not evaluate AI solely through the lens of efficiency.

It should also consider cognitive sustainability.

A successful AI implementation is not simply one that processes information faster.

It is one that reduces unnecessary mental burden while preserving accuracy, accountability, and trust.

The organisations that benefit most from AI may ultimately be those that recognise both dimensions simultaneously.

Final Thought

AI has the potential to transform healthcare, research, and regulatory operations.

However, before it reduces cognitive workload, many professionals may experience a period where decision-making becomes more psychologically demanding.

They will spend time validating outputs, assessing recommendations, and determining where trust is appropriate.

This is not evidence that AI is failing.

It is proof positive that life sciences professionals are precisely doing what they need to be doing, making judicious use of human judgment in places where precision really counts.

The longer-term potential of AI remains very real.

The immediate issue lies in figuring out how to incorporate AI without generating additional cognitive load.

 

Author Bio:

    Deepak Shukla, Founder, Wellness in Italy
    References:
    • Goddard K, Roudsari A, Wyatt JC. Automation Bias: A Systematic Review of Frequency, Effect Mediators, and Mitigators. Journal of the American Medical Informatics Association. 2012;19(1):121–127. DOI: 10.1136/amiajnl-2011-000089.
    • Lyell D, Coiera E. Automation Bias and Verification Complexity: A Systematic Review. Journal of the American Medical Informatics Association. 2017;24(2):423–431. DOI: 10.1093/jamia/ocw105.
    • Knop M, Weber S, Mueller M, Niehaves B. Human Factors and Technological Characteristics Influencing the Interaction of Medical Professionals With Artificial Intelligence–Enabled Clinical Decision Support Systems: Literature Review. JMIR Human Factors. 2022;9(1):e28639. DOI: 10.2196/28639.
    The views expressed in this article are those of the author and do not represent the editorial position of Life Science Daily News. Contributors may have a commercial interest in the topics they write about. For more information see our Contributor Policy

    Articles that may be of interest

    The Scaling Crisis in Cell and Gene Therapy

    The Scaling Crisis in Cell and Gene Therapy

    There are FDA-approved therapies on the market today that can permanently resolve a disease in a single administration, for a price of one to three million dollars. The reimbursement system responsible for covering that cost was built around medications that people...

    read more
    The Sourcing Channel Moved East

    The Sourcing Channel Moved East

    A record year of out-licensing pulled the West's early pipeline sourcing toward Shanghai and Suzhou. The discount that started it is already being competed away. What outlasts it is a two-source model for global pharma innovation. For most of the past decade, a...

    read more
    Kailera Therapeutics IPO: A $625M Signal for Biotech

    Kailera Therapeutics IPO: A $625M Signal for Biotech

    When Kailera Therapeutics priced its initial public offering on 16 April 2026, it did more than raise money. The Kailera Therapeutics IPO set a new benchmark for an industry that had spent the better part of three years in the wilderness. Priced at $625 million, it...

    read more
    Biotech’s Missing Ingredient: Execution

    Biotech’s Missing Ingredient: Execution

    Biotech has never lacked scientific innovation. What the industry continues to underestimate is how difficult it is to turn promising science into an actual therapy that reaches patients.  Over the last several years, I have seen strong assets struggle for reasons...

    read more

    Articles that may be of interest

    The Scaling Crisis in Cell and Gene Therapy

    The Scaling Crisis in Cell and Gene Therapy

    There are FDA-approved therapies on the market today that can permanently resolve a disease in a single administration, for a price of one to three million dollars. The reimbursement system responsible for covering that cost was built around medications that people...

    read more
    The Sourcing Channel Moved East

    The Sourcing Channel Moved East

    A record year of out-licensing pulled the West's early pipeline sourcing toward Shanghai and Suzhou. The discount that started it is already being competed away. What outlasts it is a two-source model for global pharma innovation. For most of the past decade, a...

    read more
    Kailera Therapeutics IPO: A $625M Signal for Biotech

    Kailera Therapeutics IPO: A $625M Signal for Biotech

    When Kailera Therapeutics priced its initial public offering on 16 April 2026, it did more than raise money. The Kailera Therapeutics IPO set a new benchmark for an industry that had spent the better part of three years in the wilderness. Priced at $625 million, it...

    read more
    Biotech’s Missing Ingredient: Execution

    Biotech’s Missing Ingredient: Execution

    Biotech has never lacked scientific innovation. What the industry continues to underestimate is how difficult it is to turn promising science into an actual therapy that reaches patients.  Over the last several years, I have seen strong assets struggle for reasons...

    read more